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Kate Stringaris,1 Sharon Adams,2 Marcela Uribe,2 Rhoda Eniafe,1 Colin O. Wu,3
Bipin N. Savani,4 A. John Barrett1Stem cell transplantation (SCT) from a healthy donor can be curative for patients with hematologic
malignancies resistant to other treatments. Elimination of malignant cells through a graft-versus-leukemia
(GVL) effect involves donor T and natural killer (NK) cells, but their relative contribution to this process
is poorly defined. NK cell alloreactivity and GVL effects are controlled by the nature of the interaction of
NK activation receptors and killer-immunoglobulin-like-receptors (KIR) with major histocompatibility locus
class I antigens on the target cell.We performed KIR-genotyping of HLA-identical sibling donors in 246 T cell-
depleted SCTs to identify genetic factors affecting transplant outcome (treatment-related mortality [TRM],
leukemic relapse, and survival). Univariate and multivariate analysis of transplant-related risk factors and KIR
genotyping was performed to identify independent variables predictive of outcome for different forms of leu-
kemia. Further to confirming known predictive factors for TRM and survival (CD34 cell dose, patient age,
disease stage), statistical analysis revealed that 3 donor B haplotype KIR genes, 2DL5A, 2DS1, and 3DS1,
were associated with significantly less relapse in patients with acute myelogenous leukemia (AML) (13% ver-
sus 57%) but not in patients with other myelogenous or lymphoid malignancies. AML patients receiving SCT
from donors with these KIR genes relapsed 4 times less frequently than patients transplanted from donors
with other KIR genotypes. These findings suggest specific, genetically determined, interactions between NK
cells and AML cells that facilitate the GVL effect, and have implications for donor selection for AML patients.
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6/j.bbmt.2010.03.004(TRM) and not to reduction in leukemic relapse,
which still accounts for about one-third of treatment
failures. Relapse represents a failure of the condition-
ing regimen or the alloimmune graft-versus-leukemia
(GVL) effect. Both T-lymphocytes and natural killer
(NK) cells have GVL effects, but the exact mechanism
by which these 2 cell types contribute to leukemia cure
after SCT is not known, and probably varies according
to disease type, transplant conditions, and donor-
recipient match. Several studies have drawn attention
to the predictive value for relapse and survival of the
lymphocyte count approximately 1 month after HLA
identical SCT for leukemia [1-6]. In a previous small
series of 54 patients receiving T cell-depleted alloge-
neic SCT from HLA identical donors, we showed
that outcome, and especially relapse risk, was linked
to NK cell and not T cell recovery [7]. Because NK
alloreactivity is determined by mismatches between
recipient HLA class I group and NK cell killer
immunoglobulin-like (KIR) receptor expression [8],1257
Table 1. Patient Characteristics
Age
Median 36 years (range: 9-66)
Sex
Male 146 (56%)
Female 115 (44%)
Race
Asian 35 (13%)
African/American 25 (10%)
Hispanic 131 (50%)
Caucasian 70 (27%)
Disease
ALL 40 (15%)
AML 70 (27%)
CML 99 (38%)
MDS 39 (15%)
CLL/NHL/MM 13 (5%)
Disease risk group
Standard risk 105 (40%)
High risk 156 (60%)
Graft type
Bone marrow 41 (16%)
Peripheral blood Stem Cells 220 (84%)
CD34+ dose
Median 5  106/kg (range 0.5-16)
CD3+ dose
Median 0.5  105/kg (range 0.005-3)
Acute GVHD
Grade 0-1 107 (57%)
Grade 2-4 81 (43%)
No GVHD data 72
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myelogenous leukemia; GVHD, graft-versus-
host disease; MDS, myelodysplastic syndrome; MM, multiple myeloma;
NHL, non-Hodgkin lymphoma.
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KIR genetics in the recipient and donor to determine
whether allo-disparity or specific KIR genotypes
were predictive of relapse. In the multivariate analysis,
only NK count at day 30 posttransplant emerged as
a significant factor affecting outcome, but, in the uni-
variate analysis, a number of donor KIR factors were
significant. In particular, donor KIR genes 2DL5A,
2DS1, and 3DS1 (which are highly correlated, indicat-
ing that they are usually inherited together), were asso-
ciated with a significantly reduced relapse rate and
improved survival [7]. Similar results have been re-
ported in recipients of unrelated donor SCT: in
a group of acute myelogenous leukemia (AML) recip-
ients, donors with KIR haplotype B (which includes
2DL5A/2DS1/3DS1) had less relapse and more favor-
able outcome after SCT than recipients of donors
without these genes [9]. It therefore appears that donor
KIR genetics may influence the risk of relapse, at least
in patients with myelogenous leukemia.
In this study, we set out to better define the contri-
bution of KIR genotype to transplant outcome in spe-
cific disease types by analyzing 261 related donor
transplants for leukemia performed at the National In-
stitutes of Health (NIH) in the 15-year period of 1993
to 2008. KIR genotype, KIR haplotype, and inheri-
tance of genes 2DL5A, 2DS1, and 3DS1were included
in univariate and multivariate analyses of transplant
variables. Our findings show that in this matched sib-
ling transplant population, it is not the presence of
the activating B haplotype, but the presence of 3 par-
ticular donor genes within haplotype B that is associ-
ated with reduced relapse. This study showed that
these 3 ‘‘favorable’’ donor KIR genes are only benefi-
cial in patients with de novo AML and not other forms
of leukemia.MATERIALS AND METHODS
Study Population
Two hundred sixty-one consecutive patients re-
ceiving HLA identical sibling allografts at the NHLBI
between 1993 and May 2008 were included in the
study. Of these, 246 had donor samples available for
KIR typing. This cohort of 246 was fully representa-
tive in terms of disease type and outcome. Patients re-
ceived conditioning with cyclophosphamide 120 mg/
kg and fractionated total body irradiation (TBI)
(400-1300 cGy) with or without fludarabine 125 mg/
m2 followed by T cell-depleted CD34 cell selected
SCT and cyclosporine as the single posttransplant
prophylaxis for graft-versus-host disease (GVHD).
Donor samples for KIR DNA typing consisted of
239 cryopreserved donor cell samples and 7 buccal
swabs. All patients and donors were enrolled onto
NHH treatment protocols and provided writteninformed consent. Follow-up ranged from 6 months
to 15 years. Patient characteristics are described in
Table 1.
DNA Extraction and KIR Typing
Genomic donor DNA was extracted from frozen
cell samples or buccal swabs using the Qiagen
column-based method (Qiamp midi kit, Qiagen,
Chatsworth, CA). Each donor was KIR typed using
0.92 mg DNA for polymerase chain reaction (PCR).
Sequence-specific primers (Invitrogen KIR Genotyp-
ing SSP kit, Invitrogen, Carlsbad, CA) were used to
amplify the DNA, and each KIR gene was identified
by the presence or absence of a band on 1.5% agarose
electrophoresis gel stained with ethidium bromide.
Fifteen KIR genes and 2 pseudogenes as well as the
common variants of 2DL5, 2DS4, and 3DP1 were
identified.
Patterns of Donor KIR Inheritance
First, we examined the ‘‘missing KIR ligand’’
model [10-12] by identifying patients missing an
HLA-A, -Bw, or -C ligand for which their donor had
an inhibitory KIR (a situation possible in the HLA
matched setting as HLA and KIR genes segregate
separately on different chromosomes). We did not
evaluate the reverse situation, where donors were
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rejection were seen. We then assessed the donor KIR
genes separately to identify whether individual KIRs
are associated with differences in outcome measures
in univariate analysis. The presence in the donor of 3
favorable KIR genes 2DL5A, 2DS1, and 3DS1
together was then examined. The impact of donor
haplotype B (defined by the presence of at least 1 of
the genes 2DL5A, 2DS1, 3DS1, 2DS2, 2DS3, or
2DS5) as well as the total number of activating and
inhibitory KIR [13], were also assessed.Statistical Method
Baseline patient characteristics and transplant
outcomes were described using summary statistics,
including means, medians, percents, standard devia-
tions, and 95% confidence intervals (CIs). Univariate
and multivariate Cox Proportional Hazard Models
were used to evaluate the effects of KIR genes, disease,
and other factors on the cumulative distribution func-
tions of time to TRM, overall survival (OS) time, and
time to relapse (TTR) with right censoring. Because
there were multiple events per patient, our analyses in-
cluded both single-event Cox Proportional Hazard
Models and multiple-event competing risk models.
For the single-event analysis, we considered TRM,
OS, and TTR separately, and used 3 right censoring
schemes: (1) for the analysis of time to TRM, patients
who did not die from TRM were treated as censored;
(2) for the analysis of time to OS, patients who were
alive at the last visits were treated as censored; (3) for
the analysis of time to relapse, patients who did not re-
lapse before death or last visit were treated as censored.
Statistical inferences for the effects of KIR genes and
other covariates on the distribution functions of
TRM, OS, and TTR were summarized using the like-
lihood ratio tests, the log-rank tests, and their corre-
sponding P-values. Cumulative distributions of
TRM, OS, and TTR over days since transplant were
estimated by the Kaplan-Meier method for patients
stratified by KIR genotype, disease, and other factors.
For the multiple-event competing risk analysis
(Supplementary Table 1), we included relapse, TRM,
and non-TRM death as competing risks, and consid-
ered the marginal competing risk models with event
time defined to be the ‘‘time to first event’’ (Terry M.
Therneau and Patricia M. Grambsch, Section 8.4,
‘‘Modeling Survival Data, Extending the Cox Model,’’
2000, New York: Springer-Verlag). These models
were selected because of their simple and clinically
meaningful interpretations. Statistical inferences for
the effects of KIR genes and covariates were summa-
rized using the likelihood ratio tests and their P-values.
The correlation between KIR genes was analyzed us-
ing Pearson’s correlation coefficient. Numerical com-
putations were carried out using the S-Plus 8 (TIBCOSoftware Inc., Palo Alto, CA) and SPSS (SPSS Inc.,
Chicago, IL) statistical packages.
To evaluate the effect of donor KIR genotype and
identify KIR genes or groups of genes associated with
distinct outcomes, we did the following analyses com-
paring all outcome variables with (1) individual KIR
genes; (2) A versus B haplotype; (3) within the haplo-
type, 3 KIR genes identified as favorable from previous
study [7] versus Haplotype B genes not including 3 fa-
vorable KIR; (4) favorable KIR with versus without
other B-haplotype-defining genes; (5) with favorable
KIR (all B haplotype) versus without favorable KIR
(only 44% being B haplotype).Definitions
Donors possessing all 3 of the KIR genes 2DL5A,
2DS1, and 3DS1 (coinherited with correlation coeffi-
cients of 0.86-0.96), were termed to have favorable
KIR. Of the 246 donors KIR typed, 33% (87) had all
three 2DL5a, 2DS1, and 3DS1 genes, and only these
87 are defined as having favorable KIR.When we wid-
ened the definition of ‘‘favorable’’ KIR to include those
with just 1 or 2 of the 3 genes, our results were less sig-
nificant. Standard patient risk group was defined as
AML or acute lymphoblastic leukemia (ALL) in first
complete remission (CR1), chronicmylogenous leuke-
mia (CML) in first chronic phase, and myelodysplastic
syndrome (MDS) intermediate-1 by WHO classifica-
tion; all other patients were categorized as high risk.
Relapse was defined as hematologic relapse. In consid-
ering missing KIR ligands, we looked at C1
(Cw*01,03,07,08,12,13,14), C2 (Cw*02,04,05,06,15,
1602, 17,18), HLA G, HLA Bw4 (B*51,52,53,57,58,
08,13,27,37,44 and A*23,24,32), and A*03 and A*11.
For example, if the patient was homozygous for
HLA-C1, -C2, or -Bw6 (and therefore had no C2,
C1, or Bw4 ligands, respectively) and the correspond-
ing inhibitory KIR receptor 2DL3, 2DL1 or 3DL1
was present in the donor (as they are in the majority
of individuals), this combination would be classified
as missing a KIR ligand.RESULTS
Outcome after SCT
The cohort consisted of 261 patients. Themajority
of patients (85%) had myelogenous diseases, of whom
70 (27%) had AML. There were significant differences
between diseases in relapse andOSwith the highest re-
lapse rates in AML and ALL (see Table 2.)
Univariate analysis of variables affecting transplant
outcome (Supplementary Table 2) showed that, as ex-
pected, CD34 dose above 5  106/kg was associated
with less relapse, less TRM, and better survival.
High-risk patients had more relapse, more TRM,
Table 2. Transplant Outcome
No. pts (%) TRM Overall Survival Relapse GVHD Grade 2-4
Disease
AML n 5 70 (27%) 16 (23%) 30 (43%) 24 (34%) 31 (53%)
MDS n 5 39 (15%) 6 (16%) 21 (54%) 12 (31%) 4 (36%)
CML n 5 99 (38%) 23 (23%) 61 (61%) 21 (21%) 33 (40%)
CLL/NHL n 5 13 (5%) 2 (15%) 6 (46%) 4 (31%) 1 (25%)
ALL n 5 40 (15%) 8 (20%) 16 (40%) 17 (43%) 17 (43%)
Cox model P 5 .8 P 5 .022* P 5 .03* P 5 .520
All patients n 5 261 55 (21%) 134 (51%) 78 (30%) 85 (44%)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leuke-
mia; NHL, non-Hodgkin lymphoma; TRM, treatment-related mortality. Bold type with asterisk indicates a p value significant at the level of 0.05 or below.
GVHD data available in 188 patients. Cox model comparing difference in outcomes between diseases.
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higher lymphocyte count at day 30 posttransplant
(LC30), and later transplant era, were all associated
with reduced TRM, but they did not affect survival
or relapse rates. The only KIR-related variable to af-
fect outcome was the possession by the donor of the
3 favorable KIR genes that were associated with re-
duced relapse and improved OS. No other KIR-
related variable affected transplant outcome, including
any single KIR gene, missing donor KIR ligand, pres-
ence of donor haplotype B, total number of inhibitory
KIR, and total number of activatory KIR.
In multivariate analysis (Table 3), high-risk disease
was associated with more relapse, more TRM, and
lower survival rates. Higher LC30 was associated
with less TRM (P 5 .015) (Figure 1A) but did not in-
dependently affect risk of relapse or OS. Better OS was
seen in recipients of a CD34 cell dose .5  106/kg.Table 3. Multivariate Analysis of Significant Risk Factors in
Cox Models
Hazard Ratio 95% CI P-Value
Relapse
High-risk disease 4.65 2.6-8.4 <.001*
CD34 >5  106/kg 0.64 0.4-1.0 .64
Donor-favorable KIR 0.54 0.3-0.9 .02*
Overall survival
High-risk disease 3.1 2.0-4.7 <.001*
CD34 >5  106/kg 0.54 0.3-0.8 .001*
Donor-favorable KIR 0.64 0.43-0.94 .024*
TRM
High-risk disease 2.36 1.3-4.3 .004*
CD34 >5  106/kg 0.55 0.3-1.0 .057
PBSC graft 0.68 0.3-1.4 .276
LC30 >600  107/L 0.42 0.2-0.9 .015*
Recent transplant era 0.95 0.5-1.8 .866
CI indicates confidence interval; KIR, killer-immunoglobulin-like recep-
tors; PBSC, peripheral blood stem cells; TRM, treatment-related mor-
tality. Bold type with asterisk indicates a p value significant at the level
of 0.05 or below.
Factors found in univariate analyses to significantly affect each outcome
measure, were analyzed in multivariate models.Impact of KIR Genes on Transplant Outcome in
Multivariate Analysis
KIR gene frequency among the donor population
studied was similar to that of published data [14-16]
and is shown in Table 4. Briefly, 90 (37%) donors
were haplotype A and 156 (63%) had at least 1 B hap-
lotype. Within the group with haplotype B, 87 (56%)
had the 3 favorable KIR genes and 69 (44%) did not.
Within those of B haplotype who had favorable KIR,
41 had 1, 30 had 2, and 16 had 3 other B-defining
KIR genes in addition to the favorable 3. This fre-
quency distribution allowed us to make robust statisti-
cal comparisons between haplotype A versus B and
within haplotype B between donors who had ‘‘favor-
able’’ KIR versus those who did not. In multivariate
analysis there was no significant difference between
A and B haplotype on outcome. In this sample of 246
patients for whom donor KIR results were available,
the presence of the 3 favorable donor KIR genes
2DL5A, 2DS1, and 3DS1 occurred in 87 cases (35%
of donors). In multivariate analysis, patients trans-
planted from donors with the 3 favorable KIR genes
had significantly less relapse (P 5 .02) (Figure 1B).When we compared outcome following transplants
from donors with the 3 favorable KIR genes, 1 or 2 fa-
vorable KIR genes, or the 3 favorable genes plus 1, 2,
or 3 additional B haplotype genes, versus the remain-
der population, possession of the 3 favorable KIR
genes discriminated best for the patient group who
had least relapse. In fact, of the 68 AML recipients of
transplants, only 3 of 23 patients from donors possess-
ing the 3 favorable KIR relapsed, whereas 20 relapses
occured in the 45 AML patients transplanted from
donors with other KIR combinations. Therefore, the
favorable component of the B haplotype was best de-
scribed as the 3 closely inherited KIR genes 2DL5a,
2DS1, and 3DS1, previously identified as favorable
genes.
Impact of Donor KIR Genes in Individual
Diseases
Relapse
Because relapse rates were different in different
diseases, we selected factors that significantly affected
relapse rates in multivariate analysis, and studied
Figure 1. Factors affecting SCToutcome in multivariate analysis of 261 patients. (A) Lymphocyte count at day 30 posttransplant and TRM; (B) donor
KIR genotype and relapse.
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of favorable donor KIR genes on relapse was restricted
to patients with AML. Patients receiving transplants
from donors with favorable KIR were 4 times less
likely to relapse than recipients of donors not possess-
ing favorable KIR (P5 .02, hazard ratio [HR]5 0.24)
(Figure 2A). The protective effect of favorable KIR on
relapse was observed in both standard and high-risk
AML patients (Figure 2B). None of the 13 patients
with standard-risk AML receiving SCT from favorable
KIR donors relapsed, whereas 19 standard risk patients
receiving SCT from donors without favorable KIR
had a 32% relapse rate. Similarly, patients with high-
risk AML receiving SCT from favorable KIR donors
had a relapse rate of 30%, whereas high-risk patient re-
cipients of SCT from donors without favorable KIR
had a 70% relapse rate. In diseases other than AML,
neither favorable KIR, nor any other KIR-related vari-
able, affected relapse, survival, or TRM (data not
shown).Table 4. Distribution of KIR Groups Among Donors
Different Ways of Grouping Donors No. (%) in Each Group
Haplotype A/A 90 (37% of 246)
At least one B Haplotype 156 (63% of 246)
Within Haplotype B: with 2DL5a,
2DS1,3DS1 (Fav KIR)
87 (56% of 156)
Within Haplotype B: without 2DL5a,
2DS1,3DS1
69 (44% of 156)
Within Haplotype B with Fav KIR: with
1 other B-defining gene
41(47% of 87)
Within Haplotype B with Fav KIR: with
2 other B-defining genes
30 (34% of 87)
Within B with Fav KIR: with 3 other B
defining genes
16 (18% of 87)
With ‘‘favorable’’ KIR genes 2DL5a/
2DS1/3DS1
89 (35% of 246)
No ‘‘favorable’’ KIR genes 157 (65% of 246)
Within no fav KIR genes: with other B
defining genes
69 (44% of 157)
Within no fav KIR genes: without other
B defining genes
90 (56% of 157)
KIR indicates killer-immunoglobulin-like receptors.TRM
In the entire cohort of 261 patients, LC30 and
high-risk disease were significant for TRM in multi-
variate analysis. In disease subsets, LC30 below 600
 107/L was again significant for TRM in AML
(45% versus 9.5% for LC30 greater than the median;
P 5 .04) and MDS (28% versus 4.8%, respectively;
P 5 .047), but not in CML. In CML, TRM was af-
fected by risk group with high risk patients having
a higher TRM (39% versus 14%; P 5 .005) and by
CD34 count with higher TRM for CD34 counts be-
low the median (32% versus 12%; P 5 .022). In
ALL, only bone marrow (BM) as the stem cell source
was a significant risk factor for higher TRM (P5 .043).
OS
Disease risk, CD34 cell dose, and a donor with
favorable KIR significantly affected OS in the entire
cohort. In disease subsets, disease risk and CD34
cell dose were still significant in AML (for risk
group: 63% survival for low risk versus 26% for
high, P 5 .004; for CD34 dose: 21% below versus
64% above median dose, P 5 .001). CD34 dose was
also significant for survival in CML (28% below versus
79% above median dose).DISCUSSION
In this study, we analyzed factors affecting trans-
plant outcome in a cohort of 261 patients with
hematologic malignancies undergoing T-depleted
myeloablative SCT. Out of many single gene analyses
and many combinations within and without the B hap-
lotype, we identified 3 donor KIR genes (2DL5A,
2DS1, and 3DS1) associated with a reduced AML re-
lapse rate post-SCT. Our findings suggest that an
NK-mediated GVL effect in AML may be modulated
by specific KIR genes in the donor. Studying the deter-
minants of SCT outcome can identify risk factors that
can be used to optimize transplant schedule design and
Table 5. Effect of Favorable Donor KIR Genes on Transplant Outcome in Different Diseases
Patient Group with Donor KIR Group TRM P HR Survival HR P Relapse HR P
AML + Fav KIR donor (n 5 23) 6 (26%) .8 1.14 13 (57%) 0.59 .151 3 (13%) 0.24 .02*
Not fav (n 5 45) 9 (20%) 17 (38%) 20 (57%)
AML + haplo B donor (n 5 46) 10 (22%) .92 0.95 20 (44%) 1.07 .86 15 (33%) 0.86 .73
Not haplo B donor (n 5 22) 5 (23%) 10 (46%) 8 (36%)
MDS + Fav (n 5 16) 1 (6%) .53 0.46 10 (63%) 0.56 .28 6 (37%) 0.61 .412
Not fav (n 5 17) 2 (12%) 8 (47%) 6 (35%)
CML + Fav (n 5 32) 6 (19%) .52 0.73 21 (66%) 0.78 .47 6 (19%) 0.75 .55
Not fav (n 5 63) 15 (24%) 38 (60%) 14 (22%)
CLL/NHL + Fav (n 5 4) 0 (0%) .56 0.03 3 (75%) 0.01 .22 0 (0%) 0.02 .37
Not fav (n 5 9) 2 (22%) 3 (33%) 4 (44%)
ALL + Fav (n 5 12) 2 (17%) .82 0.83 4 (33%) 1.21 .66 6 (50%) .417
Not fav (n512) 5 (20%) 11 (44%) 9 (36%)
High risk + Fav (n 5 50) 8 (16%) .1 0.51 24 (48%) 0.59 .02* 19 (38%) 0.63 .1
Not Fav (n 5 94) 25 (27%) 31 (33%) 41 (44%)
Std risk Fav (n 5 37) 7 (19%) .43 1.51 27 (73%) 0.88 .74 2 (5%) 0.27 .09
Not Fav (n 5 65) 8 (12%) 46 (71%) 12 (18%)
TRM indicates treatment-related mortality; HR, hazard ratio; Fav, stem cell transplant (SCT) donor with 3 favorable KIR genes 2DL5A/2DS1/3DS1; Not
Fav, SCT donor without all 3 genes; Standard risk, acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in first complete remission,
chronic myeloid leukemia (CML) in first chronic phase, and myelodysplastic syndrome (MDS) intermediate-1 byWHO classification; High risk, all other
patients. Two hundred forty-six patients had donor samples available for killer-immunoglobulin-like-receptors (KIR) typing. Bold type with asterisk in-
dicates a p value significant at the level of 0.05 or below.
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point to biologic mechanisms underlying success or
failure of SCT. In addition to well-recognized dis-
ease-related factors predicting outcome, we and others
have identified CD341 cell dose and lymphocyte
counts 30 days after SCT as predictive factors for
transplant outcome [3,17,18]. In a previous analysis
on a smaller cohort of 54 patients, we found that
donor KIR genotype was also a strong predictor of
survival and relapse after SCT. In particular, 3
closely linked donor genes 2DL5A, 2DS1 and 3DS1,
of the B haplotype were predictive for outcome and
relapse [7]. We therefore extended this observation
in the present study where there were sufficient num-
bers of patients to assess the impact of donor KIR
group on outcome in different diseases. Here we
show that, in addition to known risk factors for out-
come (disease risk, disease type, CD341 cell dose,
and day 30 lymphocyte count), donor KIR genesFigure 2. Effect of donor KIR genes on relapse in AML patients (n5 68). (A) S
group.2DL5A, 2DS1 and 3DS1 were associated with signifi-
cantly reduced relapse rates after T-depleted SCT.
This effect was restricted to patients with de novo
AML and was not significant in CML, MDS, or lym-
phoid malignancies.
The impact of donor KIR on relapse in AML was
striking: actuarial relapse was 13% in recipients of
transplants from donors with favorable KIR and 57%
in recipients whose donors lacked these genes
(P 5 .02). The effect of donor KIR was seen in both
standard and high-risk AML: no standard-risk patient
receiving a transplant from a donor with favorable KIR
relapsed, compared with 32% relapse rates for
standard-risk recipients of donors with unfavorable
KIR. Similarly, relapse rates for high-risk patients
were affected by donor KIR group: 30% for recipients
with favorable KIR donors and 70% for recipients with
unfavorable KIR donors. Because the 3 favorable genes
are usually inherited together, it is impossible totratified by donor KIR genes; (B) stratified by donor KIR and patient risk
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Leukemia Relapse After SCTdetermine whether all 3, or only 1 KIR gene acts as
a protective factor. Because 1 of the 3 genes occurs
in only 5% of donors, very large patient cohorts would
be required to explore the contribution of specific fa-
vorable KIR. Nevertheless, 4 donors who had only
3DS1 (grouped as ‘‘unfavorable’’ as they did not have
all 3 favorable genes), conferred poor outcomes (3
died of relapse within 6 months of transplant and 1
from alveolar hemorrahage) indicating that perhaps
3DS1 is not the gene of interest.
Our results differ significantly from those of a re-
cent analysis in AML patients receiving unrelated do-
nor SCT, where SCT from donors of the B haplotype
(which contains the favorable KIR genes) were associ-
ated with less relapse. As there is strong linkage dis-
equilibrium among B haplotype genes it is difficult to
be certain which genes are associated with the antileu-
kemic effect. The statistical problems associated with
multiple comparisons mean the results must be viewed
cautiously. However, in this study, the strongest asso-
ciation with reduced AML relapse was with the KIR
genes 2DL5A, 2DS1 and 3DS1 (P 5 .02, HR 5
0.24) and analysis of the B haplotype itself was not
found to be significant (P5 .73, HR5 0.86). Our find-
ings contrast with data by Hsu et al. [11], who studied
the role of donor KIR in a mixed disease population of
patients receiving identical sibling, T cell-depleted
SCT similar to ours, and found no benefit for the pres-
ence of any particular donor KIR on outcome. Al-
though we found that missing a ligand for donor
KIR reducedTRM in AML patients, we could not rep-
licate their findings of less relapse and improved sur-
vival in these patients. The difference may be
explained by the fact that patients in Hsu et al.’s study
all received BM grafts, whereas the majority of our pa-
tients received peripheral blood SCT. A separate anal-
ysis of the 39 BM recipients in our series did not show
any impact of donor KIR groups, whereas the associa-
tion between donor KIR and relapse was of greater
significance when the peripheral blood stem cell trans-
plants (PBSCTs) were analyzed separately (P\ .029).
Further analysis of larger patient series receiving
different types of transplant regimens is required to
clarify these differences. The disease specificity of
our finding, with the impact of KIR group genetics
mainly affecting AML, is consistent with findings
from other centers where NK-KIR-mediated effects
have been found to be strongest in AML [10,11] as
well as studies showing that alloreactive NK cells do
not kill ALL cells in vitro [19].
The mechanism whereby KIR genes 2DL5A,
2DS1, and 3DS1mediate a protective effect against re-
lapse is unclear. Our previous small study linked these
genes to higher NK cell counts post transplant sug-
gesting a genetic control ofNK cell recovery [7]. Inter-
estingly, in our larger sample, we did not find an
association of these genes with higher lymphocytecounts post transplant, but in the small group of
patients who did not achieve lymphocyte counts above
0.2 109/L, the positive effect of these KIR genes was
not seen, suggesting that a minimum level of NK cells
need to be present for the effect of KIR genes to be fa-
cilitated. The association between favorable KIR and
lower relapse rates was also stronger in peripheral
blood stem cell transplantation, where higher circulat-
ing levels of all cells including NK occur earlier after
transplant, than with BM grafts.
Our results suggest that there may be specific li-
gands on the surface of AML cells that make the inter-
action between favorable KIR receptors and AML cells
particularly effective at causing NK-mediated AML
cell death. Alternatively, these favorable KIR genes
may simply represent a marker linked to an as yet un-
defined GVL pathway. Further studies are required to
investigate this and determine whether the beneficial
KIR-AML interaction is restricted to specific AML
subtypes and reproduced in HLA matched but unre-
lated SCT.
Our findings have practical implications and sup-
port the concept of selecting donors by KIR genotype
to optimize GVL effects after SCT for AML. In the
absence of a favorable donor, patients could be consid-
ered for experimental treatments to boost GVL, for
example, using NK infusions or lower doses of immu-
nosuppression. Recent trials using allogeneic NK cell
infusions to boost immunity post transplant are prom-
ising [20-22]. Selecting donors with favorable KIR
could potentially increase the ability of such
infusions to control leukemia and prevent relapse.
This would be a practical possibility because donors
with favorable KIR genes represent up to 40% of the
population.
Financial disclosure: The authors have nothing to
disclose.SUPPLEMENTARY DATA
Supplementary data associated with this article can
be found, in the online version, at doi:10.1016/
j.bbmt.2010.03.004.REFERENCES
1. Kumar S, Chen MG, Gastineau DA, et al. Effect of slow lym-
phocyte recovery and type of graft-versus-host disease prophy-
laxis on relapse after allogeneic bone marrow transplantation
for acute myelogenous leukemia. Bone Marrow Transplant.
2001;28:951-956.
2. Kumar S, ChenMG, Gastineau DA, et al. Lymphocyte recovery
after allogeneic bone marrow transplantation predicts risk of re-
lapse in acute lymphoblastic leukemia. Leukemia. 2003;17:
1865-1870.
3. KimDH, Kim JG, Sohn SK, et al. Clinical impact of early abso-
lute lymphocyte count after allogeneic stem cell transplantation.
Br J Haematol. 2004;125:217-224.
1264 Biol Blood Marrow Transplant 16:1257-1264, 2010K. Stringaris et al.4. Savani BN, Mielke S, Rezvani K, et al. Absolute lymphocyte
count on day 30 is a surrogate for robust hematopoietic recovery
and strongly predicts outcome after T cell-depleted allogeneic
stem cell transplantation. Biol Blood Marrow Transplant. 2007;
13:1216-1223.
5. IshaqiMK,Afzal S,DupuisA,Doyle J,GassasA.Early lymphocyte
recoverypost-allogeneic hematopoietic stemcell transplantation is
associated with significant graft-versus-leukemia effect without
increase in graft-versus-host disease inpediatric acute lymphoblas-
tic leukemia. Bone Marrow Transplant. 2008;41:245-252.
6. Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-
Kriesche HU, Reddy V. The relationship between circulating
natural killer cells after reduced intensity conditioning hemato-
poietic stem cell transplantation and relapse-free survival and
graft-versus-host disease. Haematologica. 2008;93:1852-1858.
7. Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell
recovery determines outcome after T-cell-depleted HLA-
identical stem cell transplantation in patients with myeloid leu-
kemias but not with acute lymphoblastic leukemia. Leukemia.
2007;21:2145-2152.
8. Ljunggren HG, Karre K. In search of the ‘‘missing self’’: MHC
molecules and NK cell recognition. Immunol Today. 1990;11:
237-244.
9. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with
group B KIR haplotypes improve relapse-free survival after un-
related hematopoietic cell transplantation for acute myeloge-
nous leukemia. Blood. 2009;15(113):726-732.
10. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor
natural killer cell alloreactivity in mismatched hematopoietic
transplants. Science. 2002;295:2097-2100.
11. HsuKC,Keever-TaylorCA,WiltonA, et al. Improved outcome
in HLA-identical sibling hematopoietic stem-cell transplanta-
tion for acute myelogenous leukemia predicted by KIR and
HLA genotypes. Blood. 2005;105:4878-4884.
12. LeungW, Iyengar R, Turner V, et al. Determinants of antileuke-
mia effects of allogeneic NK cells. J Immunol. 2004;172:644-650.
13. Kroger N, Binder T, Zabelina T, et al. Low number of donor
activating killer immunoglobulin-like receptors (KIR) genesbut not KIR-ligand mismatch prevents relapse and improves
disease-free survival in leukemia patients after in vivo T-cell de-
pleted unrelated stem cell transplantation.Transplantation. 2006;
82:1024-1030.
14. Witt CS, Dewing C, Sayer DC, Uhrberg M, Parham P,
Christiansen FT. Population frequencies and putative haplo-
types of the killer cell immunoglobulin-like receptor sequences
and evidence for recombination. Transplantation. 1999;68:
1784-1789.
15. CookMA, Milligan DW, Fegan CD, et al. The impact of donor
KIR and patient HLA-C genotypes on outcome following
HLA-identical sibling hematopoietic stem cell transplantation
for myeloid leukemia. Blood. 2004;103:1521-1526.
16. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele
frequency database: http://www.allelefrequencies.net. Tissue
Antigens. 2003;61:403–407.
17. Ringden O, Barrett AJ, Zhang MJ, et al. Decreased treatment
failure in recipients of HLA-identical bone marrow or periph-
eral blood stem cell transplants with high CD34 cell doses. Br
J Haematol. 2003;121:874-885.
18. Savani BN, Rezvani K, Mielke S, et al. Factors associated with
early molecular remission after T cell-depleted allogeneic stem
cell transplantation for chronic myelogenous leukemia. Blood.
2006;107:1688-1695.
19. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer
cell alloreactivity in HLA-mismatched hematopoietic stem cell
transplantation. Blood. 1999;94:333-339.
20. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful
adoptive transfer and in vivo expansion of human haploidentical
NK cells in patients with cancer. Blood. 2005;105:3051-3057.
21. Berg M, Lundqvist A, McCoy P Jr., et al. Clinical-grade ex
vivo-expanded human natural killer cells up-regulate activating
receptors and death receptor ligands and have enhanced cyto-
lytic activity against tumor cells. Cytotherapy. 2009;11:341-355.
22. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor
NK-lymphocyte infusion to consolidate engraftment after
haploidentical stem cell transplantation. Leukemia. 2004;18:
1835-1838.
